Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of H56:IC31 in Reducing the Rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs H56IC (Primary)
- Indications Pulmonary tuberculosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Aeras
- 05 Mar 2019 Last checked against Pan-African Clinical Trials Registry
- 05 Feb 2019 Planned End Date changed from 30 Dec 2020 to 31 Dec 2022.
- 05 Feb 2019 Planned primary completion date changed from 30 Sep 2020 to 6 Apr 2022.